Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19/CD20 Dual-Target in vivo CAR-T Lentiviral in Relapsed/Refractory B-cell Malignancies
NCT07763938Phase 1Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Nov 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in B-cell malignancy, sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Incidence, severity, and category of treatment-emergent adverse events at 2 years, Objective Response Rate at 2 years and 1 more. Planned start Nov 2026; status: not yet recruiting.
02
Conditions
B-cell malignancy
Beyond the preview
Go deeper on NCT07763938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07763938.